Osteoporosis treatment gap prior to femoral fracture and prevalence of pharmacological risk factors: a prospective observational study - Report - MDSpire
Advertisement
Osteoporosis treatment gap prior to femoral fracture and prevalence of pharmacological risk factors: a prospective observational study
Clinical Report: Addressing the Treatment Deficiency for Osteoporosis Before Hip Fractures
Overview
This study evaluates the guideline concordance of osteoporosis therapy in patients admitted with hip fractures and quantifies the prevalence of medications associated with increased fall and fracture risk.
Background
Osteoporosis is a major public health concern, particularly in older adults, as it leads to severe consequences such as hip fractures, which are associated with high morbidity and mortality. Despite effective pharmacological treatments, many patients do not receive appropriate therapy following fragility fractures, particularly hip fractures.
Data Highlights
No numerical data available in the provided source material.
Key Findings
Hip fractures have a one-year mortality rate approaching 20% and increase the risk of subsequent fractures.
Austria has one of the highest incidences of hip fractures in Europe.
Current guidelines emphasize a risk-based approach to osteoporosis treatment initiation.
Medication-related risk factors, particularly fall-risk-increasing drugs (FRIDs), contribute to fracture risk in older adults.
Structured medication reviews are recommended to identify potentially inappropriate medications.
Clinical Implications
Conducting medication reviews can help identify and mitigate the risks associated with fall-risk-increasing medications.
Conclusion
The study highlights the importance of addressing medication-related risks in patients with hip fractures.
Higher annual oral corticosteroid exposure was associated with greater odds of systemic adverse events, with avascular bone necrosis and pneumonia showing dose-dependent associations with cumulative dose and osteoporosis associated with longer annual exposure duration.
